amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 hospitalized
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)	ACTIV-3 ...

1 studies excluded by filtering options 0

6456

ACTIV-2 (BRII-196 and BRII-198), 0

1

1

0

risk of bias not avaialble